Items where Subject is "Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Genetics (111203)"
![]() | Up a level |
- Subjects classification (32824)
- Australian and New Zealand Standard Research Classification (32824)
- MEDICAL AND HEALTH SCIENCES (110000) (6766)
- ONCOLOGY AND CARCINOGENESIS (111200) (348)
- Cancer Genetics (111203) (13)
- ONCOLOGY AND CARCINOGENESIS (111200) (348)
- MEDICAL AND HEALTH SCIENCES (110000) (6766)
- Australian and New Zealand Standard Research Classification (32824)
Group by: Authors/Creators | Item Type
Jump to: Book Chapter | Journal Article
Number of items at this level: 13.
Book Chapter
Lehman, Melanie & Nelson, Colleen (2013) Toward revealing the complexity of androgen responsive protein and non-coding transcripts in prostate cancer. In Wang, Zhou (Ed.) Androgen-Responsive Genes in Prostate Cancer : Regulation, Function and Clinical Applications. Springer. (In Press)
Stephenson, Sally-Anne, Mertens-Walker, Inga, & Herington, Adrian (2012) Signaling of receptor tyrosine kinases in the nucleus. In Najman, Stevo (Ed.) Current Frontiers and Perspectives in Cell Biology. InTech, Rijeka, Croatia, pp. 211-234.
Journal Article
Amin Al Olama, A., Kote-Jarai, Z., Schumacher, F. R., Wiklund, F., Berndt, S. I., Benlloch, S., et al. (2012) A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 22(2), pp. 408-415.
1
1Betsou, Fotini, Gunter, Elaine, Clements, Judith, DeSouza, Yvonne, Goddard, Katrina A.B., Guadagni, Fiorella, et al. (2013) Identification of evidence-based biospecimen quality-control tools. The Journal of Molecular Diagnostics, 15(1), pp. 3-16.
Byron, Sara A., Gartside, Michael, Powell, Matthew A., Wellens, Candice L., Gao, Feng, Mutch, David G., et al. (2012) FGFR2 point mutations in 466 Endometrioid Endometrial Tumors : relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and Clinicopathological features. PLoS ONE, 7(2), e30801-e30801.
29
6
6
29
6
6Chambers, Karen F., Bacon, James R., Kemsley, E. Katherine, Mills, Robert D., Ball, Richard Y., Mithen, Richard F., et al. (2009) Gene expression profile of primary prostate epithelial and stromal cells in response to sulforaphane or iberin exposure. The Prostate, 69(13), pp. 1411-1421.
11
12
11
12Greulich, Heidi & Pollock, Pamela M. (2011) Targeting mutant fibroblast growth factor receptors in cancer. Trends in Molecular Medicine, 17(5), pp. 283-292.
173
12
10
173
12
10Jeet, Varinder, Russell, Pamela J., Verma, Nirupama D., & Khatri, Aparajita (2012) Targeting aurora kinases : a novel approach to curb the growth and chemoresistance of androgen refractory prostate cancer. Current Cancer Drug Targets, 12(2), pp. 144-163.
Lose, Felicity, Lawrence, Mitchell Graham, Srinivasan, Srilakshmi, O'Mara, Tracy, Marquart, Louise, Chambers, Suzanne, et al. (2012) Kallikrein 14 is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness. Biological Chemistry, 393(5), pp. 403-412.
3
3
3
3Morris, Christelle, Tomimatsu, Nozomi, Richard, Derek J., Cluet, David, Burma, Sandeep, Khanna, Kum Kum, et al. (2012) INT6/EIF3E interacts with ATM and is required for proper execution of the DNA damage response in human cells. Cancer Research, 72(8), pp. 2006-2016.
O’Flaherty, John D., Barr, Martin, Fennell, Dean, Richard, Derek, Reynolds, John, O’Leary, John, et al. (2012) The cancer stem-cell hypothesis : its emerging role in lung cancer biology and its relevance for future therapy. Journal of Thoracic Oncology, 7(12), pp. 1880-1890.
1
1
1
1Seim, Inge, Lubik, A. A, Lehman, Melanie, Tomlinson, N., Whiteside, Eliza J., Herington, Adrian C., et al. (2012) Cloning of a novel insulin-regulated ghrelin transcript in prostate cancer. Journal of Molecular Endocrinology.
1
1Terzian, Tamara, Torchia, Enrique C., Dai, Daisy, Robinson, Steven E., Murao, Kazutoshi, Stiegmann, Regan A., et al. (2010) p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell and Melanoma Research, 23(6), pp. 781-794.
19
18
19
18
